ctDNA and residual cancer burden are prognostic in triple-negative breast cancer patients with residual disease

Triple-negative breast cancer (TNBC) patients with residual disease (RD) after neoadjuvant systemic therapy (NAST) are at high risk for recurrence. Biomarkers to risk-stratify patients with RD could help individualize adjuvant therapy and inform future adjuvant therapy trials. We aim to investigate...

Descripción completa

Detalles Bibliográficos
Autores principales: Stecklein, Shane R., Kimler, Bruce F., Yoder, Rachel, Schwensen, Kelsey, Staley, Joshua M., Khan, Qamar J., O’Dea, Anne P., Nye, Lauren E., Elia, Manana, Heldstab, Jaimie, Home, Trisha, Hyter, Stephen, Isakova, Kamilla, Pathak, Harsh B., Godwin, Andrew K., Sharma, Priyanka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9988835/
https://www.ncbi.nlm.nih.gov/pubmed/36878909
http://dx.doi.org/10.1038/s41523-023-00512-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9988835/
https://www.ncbi.nlm.nih.gov/pubmed/36878909
http://dx.doi.org/10.1038/s41523-023-00512-7

Ejemplares similares